Tom Isett, iBio CEO

CD­MO makes an AI and drug dis­cov­ery play in lat­est, small-time ac­qui­si­tion

The CD­MO out­fit iBio has net­ted a deal that sees it gain ac­cess to an AI-based plat­form as well as new ther­a­peu­tic can­di­dates as it looks to dive fur­ther in­to drug dis­cov­ery.

iBio closed on ac­quir­ing sev­er­al as­sets from the San Diego-based biotech RubrYc Ther­a­peu­tics, snap­ping up sev­er­al on­col­o­gy pro­grams. The cost in­cludes a $1 mil­lion up­front pay­ment as well as the abil­i­ty of RubrYc’s in­vestors to re­ceive up to $5 mil­lion in mile­stones over the next sev­er­al years.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.